Spondyloarthropathy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Spondyloarthropathy Market Outlook
Thelansis’s “Spondyloarthropathy
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2024 To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Spondyloarthropathy treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
Spondyloarthropathy Overview
Spondyloarthropathy,
also referred to as spondyloarthritis, encompasses a group of inflammatory
rheumatic diseases characterized by a shared association with the HLA-B27 gene
and the presence of enthesitis as the underlying pathological lesion. The five types
of spondyloarthritis are axial spondyloarthritis (also known as ankylosing
spondylitis), psoriatic arthritis (also known as peripheral spondyloarthritis),
reactive arthritis, enteropathic arthritis, and undifferentiated
spondyloarthritis. Men and women are equally affected by psoriatic arthritis,
while males are affected more frequently by ankylosing spondylitis in a 3:1
ratio. Reactive arthritis exhibits a higher prevalence in males following a
venereal infection and equally affects men and women following a dysenteric
infection. Clinical features of spondyloarthropathies typically include a
tendency to affect spinal joints causing sacroiliitis and spondylitis,
peripheral arthritis, which is typically oligoarticular and asymmetric,
enthesitis or enthesopathy, onset at a young age, negative results for
rheumatoid factors, and a familial predisposition and strong association with
the genetic polymorphism of the major histocompatibility complex, HLA-B27.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment